Categories: News

Solo-Dex Facile(R) Peripheral Nerve Block Catheter Is Now Nationally Available

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Evaluation Program Is Open to Qualified Hospitals and Surgical Centers

WOLF CREEK, MT / ACCESSWIRE / April 19, 2021 / Solo-Dex, a developer and distributor of medical catheters, announces the national availability of its Facile® continuous peripheral nerve block (cPNB catheter for managing pain before, during and after surgery. All Solo-Dex products are currently US FDA cleared and CE marked for Europe.

With Facile®, anesthesiologists can place and activate the facile continuous nerve block catheter quickly and safely for common procedures such as shoulder repair, hip and knee replacement as well as general surgical procedures. Facile leads the field in ease-of-use placement. The SOLO-DEX Fascile® simplifies and accelerates cPNB placement, improving patient comfort and post-procedure pain management. Patients report the need for opioids is drastically reduced and often eliminated altogether.

Regional anesthesia coupled with mild sedation may eliminate the need for a patient to receive general anesthesia which requires the manipulation of the airway. Manipulation of the airway increases the risk of Covid-19 exposure for the surgical team.

“Before the introduction of Solo-Dex Facile, the use of continuous regional anesthesia has been limited to a small group. Fascile has been developed specifically for the ease-of-use market which is up to 10 times larger than the current nerve catheter market,” says Steve Eror, CEO of Solo-Dex.

Regional anesthesia established and maintained by a small catheter offers safe and effective pain management for days before, during and after surgery. The patient tends to recover more quickly and may be released for home recovery with a block that eliminates the need for oral opioid painkillers.

According to the CDC, 40 people die from overdoses involving prescription opioids. The real cost of Opioid abuse is $1 Trillion from 2001-2017 according to the NY Times.

Interested physicians can obtain more information at www.solo-dex.com

ABOUT SOLO-DEX
Solo-Dex is a developer and distributor of medical catheter, founded by leading anesthesiologists to reduce the cost and risk associated with general anesthesia by improving surgical patient recovery times, reducing medical personnel exposure to covid-19, reducing or eliminating the misuse of opioid-related pain management, and by safely and effectively managing pain before, during and after a procedure. For more information about SOLO-DEX, please log on to www.solo-dex.com

Media Contact:
Janet Vasquez, Public Relations
Solo-Dex Inc.
pr@solo-dex.com

SOURCE: Solo-Dex, Inc.

View source version on accesswire.com:
https://www.accesswire.com/640748/Solo-Dex-FacileR-Peripheral-Nerve-Block-Catheter-Is-Now-Nationally-Available

Staff

Recent Posts

Ontada Illuminates the Power of its Real-World Evidence to Improve Health Outcomes for People with Cancer at ISPOR 2025

Ontada researchers to present 14 data presentations at ISPOR 2025 including a podium presentation on…

32 minutes ago

HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

Board expansion reflects Company’s commitment to leadership and innovation in remote cardiac monitoring SANTA CLARA,…

35 minutes ago

IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment

DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers…

40 minutes ago

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

Financial results to be released before market open; Conference call to be conducted at 9:00…

40 minutes ago

Cannabix Technologies Receives NHTSA Approval for BreathLogix Workplace Series Alcohol Breathalyzer

Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of…

41 minutes ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Company continues to expand global IP coverage and claims to major markets, now extending to…

41 minutes ago